Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

2014 Annual Report of Celgene from its Chairman

3/6/2015

0 Comments

 
Summit, NJ - These are exciting times for Celgene and promising times for the patients we serve. We continue to deliver on multiple opportunities, translating the potential of transformational science into disease-altering and life-enhancing innovative medicines with the goal of helping patients with critical unmet medical needs worldwide live longer and better lives. This dedication to patients is aligned with our corporate vision, mission and values and reflects our unwavering commitment to put patients first. By advancing the course of healthcare through bold scientific pursuits and medical innovation we are making it possible for societies to progress and economies to prosper.
With our growing portfolio of innovative therapies, we are serving more patients, with new products and additional indications, in countries throughout the world. We are working to ensure that patients have access to our new innovative oral medicine POMALYST® (IMNOVID® in Europe) for third line treatment of multiple myeloma. Celgene’s ABRAXANE® is now approved for patients with metastatic pancreatic cancer. And we are also now serving patients in the field of Immunology and Inflammation with the introduction of OTEZLA®, an innovative oral treatment for patients with psoriasis and psoriatic arthritis. We continue to research and invest, advancing our own discoveries and scanning the landscape for opportunities to enhance and expand our deep and diverse portfolio of next-generation medicines that hold the potential to change the course of human health.

We currently have 22 clinical development programs, with about 28,000 patients enrolled in more than 100 Celgene-sponsored clinical trials. At the same time we are mindful that Celgene is part of an ecosystem of innovation. Our research and discovery efforts seek to collaborate with and complement the work of medical and academic institutions of excellence, government agencies and regulators, patient advocacy groups and non-governmental organizations, as well as investors and other biopharmaceutical companies.

A strong commitment to five pillars of corporate responsibility permeate our global organization: patients and communities, commitment to safety, governance, global health and environment and sustainability. Let me cite just a few highlights. Our commitment to patients extends beyond our innovative life-enhancing therapies to our pioneering patient access programs. Our Patient Support Coordinators work tirelessly to help patients gain access to the treatments they need. More than 20,000 patients have received assistance from Celgene Patient Support since 2007.

Our giving centers on patient-focused programs such as the Leukemia and Lymphoma Society’s Light the Night walks, where Celgene ranked first among biopharmaceutical companies, and the Pancreatic Cancer Action Network’s Purple Strides campaign. Our focus also extends to supporting science education through our participation in programs like Change the Equation, as well as scholarships and fellowships to help train the next generation great minds in the life sciences.

For the complete report and more: http://assets1.celgene.com/content/uploads/celgene-responsibility.pdf
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619